THERAPEUTICS

CONSTANCE THERAPEUTICS (CT) IS AWARDED THIRD PATENT BY U.S. PATENT AND TRADEMARK OFFICE.

Constance Therapeutics is pleased to announce that the third of its pending patent applications has been allowed by the U.S. Patent and Trademark Office and issued as U.S. Pat. No. 10,806,707, titled “Cannabis Oil Compositions and Methods for Preparations Thereof.”

 Claims in the patent are directed to CT’s combinations of cannabinoids and essential oils in the form of gel capsules for oral and pulmonary administration, as well as to a method for treating Lyme disease using the gel capsules.  The patent is part of CT’s larger patent portfolio, claiming priority to filings in 2015, with applications pending in the United States, Canada, Israel, the European Patent Office, Australia, Colombia and Mexico.  As such, the company’s suite of proprietary cannabis compositions and the underlying methodologies to produce them are patent pending on a global basis.

CT’s technology is based on years’ worth of research and development by the company and its founder, Constance Finley.  Finley’s first experiences in cannabis extraction were with “out of options” patients with serious medical conditions such as Stage IV cancer and chronic auto immune conditions including Lyme disease, rheumatoid arthritis and MS.  Her innovations originated in the early days of California medicinal cannabis, when the only delivery options were smoking a joint or a hash pipe.   Such methods were problematic for many and ineffective for most serous conditions.  The need for effective and non-toxic delivery methods and formulations of medicinal cannabis products set Finley on a path of research and discovery resulting in the founding of Constance Therapeutics.

Please join us in congratulating Constance Therapeutics on this accomplishment.

GET STARTED TODAY

Related Articles

Get in touch and find the
right product for you.

Contact us to begin your journey.